0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Full length CD20, HEK293 expressed

HEK293 Expressed Full Length CD20 Protein with Nanodisc / DDM

FACS Verified and Protocol Offered

The new released article Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab published on Science by Genentech team highlights the importance of having intact CD20 for antibody drug development. The team have discovered several RTX mutants that, despite maintaining cell-binding activity comparable to that of OBZ, and largely unaffected binding to the primary ECL2 epitope, are incapable of eliciting CDC. This confirms that the secondary ECL1/2 epitope and Fab:Fab interface contribute to the unique binding properties and high CDC activity of RTX.

(Download the full text at the buttom of the page.)

Lionel Rougé, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020

To help CD20 antibody drug development, the HEK293 expressed full length CD20 from ACROBiosystems has been very attractive to customers.

CD20 Full Length
Background

The 61st annual meeting of the American society of hematology (ASH) in 2019 presented bi-specific antibodies targeting CD20 on the surface of B cells and CD3 on the surface of T cells, such as CD20- TCB, with preliminary resultsof clinical studies showing acceptable safety and promising efficacy of this pair of specific antibodies.

CD20 is a hot target for the treatment of lymphoma, leukemia and some autoimmune diseases. However, due to low expression titer and the unstable bioactivity, it is so difficult to find an active CD20 protein on the market for antibody drug development and the CD20 CAR expression.

To address these issues, ACROBiosystems has developed the highly active full length multi-transmembrane CD20 proteins, expressed by HEK293 cells. The active full length CD20 proteins carry both big and small ECD loops, and bind Rituximab and Ofatumumab with high binding affinity in ELISA and SPR assay. We have different types of CD20 proteins include unconjugated protein, biotinylated proteins with DDM and Nanodisc, which are suitable for immunization, ELISA, SPR, BLI and FACS.

Different Types of CD20 Proteins
Protein with DDM.

DDM can disintegrate the lipid membrane to release the membrane protein and provide a hydrophobic environment, maintain and protect the hydrophobic transmembrane structure of membrane proteins. But it is not recommended for cell experiments because it can destroy the structure of the cell membrane.

Protein with Nanodisc.

Nanodisc is a non-covalent structure of phospholipid bilayer and membrane scaffold protein. Membrane proteins can be integrated into nanodiscs to maintain their biological activity, CD20 protein with nanodisc was recommended for cell experiments.

Product List

ACRO’s new product CD20 proteins have a complete and natural conformation and shown a high sensitivity without unspecific binding background (FACS verified). Protocols are provided for free. You can click the following link to request.

MoleculeCat. No.HostTypeProduct Description
CD20/ MS4A1CD0-H52H3HEK293                            Unconjugated Human Full Length CD20 Protein, His Tag (DDM)
See BLI/ SPR/ ELISA Data Below
CD0-H82E5HEK293                            Biotinylated Biotinylated Human Full Length CD20 Protein, His,Avitag™ (DDM)
Request FACS Protocol
CD0-H82E3HEK293 Biotinylated Biotinylated Human Full Length CD20 Protein, His,Avitag™ (Nanodisc)
Request FACS Protocol
Product Features

Full length CD20 protein has a complete conformation with both small and big loops.

Full length CD20 protein has better bioactivity

A) HEK293 Cell (Full Length)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2-16 ng/mL.

B) E.coli (Extracellular)

Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E.coli) with a linear range of 78-2500 ng/mL.

The bioactivity of full length CD20 protein was verified by ELISA/ SPR/ BLI and the protocols are offered.

BLI
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression)

Loaded MabThera® (Rituximab) on ProteinA Biosensor, can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with an affinity constant of 8.1 nM as determined in BLI assay (ForteBio Octet Red96e).

SPR
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression)

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with an affinity constant of 6.02 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K).

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200).

ELISA
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 2-16 ng/mL (in presence of DDM and CHS).

Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 1-20 ng/mL (in presence of DDM and CHS).


Customer Reviews
Latest Research on CD20 Target

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

This web search service is supported by Google Inc.

totop